Search

Showing "11155" results for ""

HIV-associated immunosuppression increases risk of liver cancer

Once-daily darunavir (Prezista) approved for first-line use in United States

CD4 decline, death more likely if change from NNRTI regimen delayed

Efavirenz superior to nevirapine for first-line treatment: African observational cohort

Start treatment at CD4 cell counts below 500, says large cohort study

Continued antiretroviral therapy reduces bone mineral density in SMART study

Darunavir effective and tolerable in treatment-experienced children and adolescents at 48 weeks

Bevirimat: good results at 400 mg liquid dose, but formulation problems persist

No significant differences between elvucitabine and 3TC at 48 weeks

Raltegravir non-inferior to efavirenz: 48 week, phase III results

Raltegravir resistance patterns becoming clearer

Vicriviroc: long-term safety concerns over cancers dispelled

Tenofovir/FTC more effective than abacavir/3TC in first-line boosted-PI regimens: meta-analysis

Initial CD4 cell counts in new seroconverters have declined over time

Superinfection seen frequently in heterosexual couples in Zambia

Once-daily darunavir/ritonavir may be an option for some treatment-experienced patients

Darunavir European license extended to all treatment-experienced

Plasma concentrations of rifampicin may be too low in children using currently recommended doses

Receive the latest HIV research and conference news

Showing "11155" results for ""

HIV-associated immunosuppression increases risk of liver cancer

Once-daily darunavir (Prezista) approved for first-line use in United States

CD4 decline, death more likely if change from NNRTI regimen delayed

Efavirenz superior to nevirapine for first-line treatment: African observational cohort

Start treatment at CD4 cell counts below 500, says large cohort study

Continued antiretroviral therapy reduces bone mineral density in SMART study

Darunavir effective and tolerable in treatment-experienced children and adolescents at 48 weeks

Bevirimat: good results at 400 mg liquid dose, but formulation problems persist

No significant differences between elvucitabine and 3TC at 48 weeks

Raltegravir non-inferior to efavirenz: 48 week, phase III results

Raltegravir resistance patterns becoming clearer

Vicriviroc: long-term safety concerns over cancers dispelled

Tenofovir/FTC more effective than abacavir/3TC in first-line boosted-PI regimens: meta-analysis

Initial CD4 cell counts in new seroconverters have declined over time

Superinfection seen frequently in heterosexual couples in Zambia

Once-daily darunavir/ritonavir may be an option for some treatment-experienced patients

Darunavir European license extended to all treatment-experienced

Plasma concentrations of rifampicin may be too low in children using currently recommended doses

Receive the latest HIV research and conference news